- Disease: Acute COVID-19
- Study type: Observational Cohort Study, Treatment
- Study type descriptors: Prospective, Single centre
- Objective: To assess the efficacy of early combination_x000D_ treatment with one antiviral and a monoclonal_x000D_ antibody, presumably active against the circulating_x000D_ SARS-CoV-2 variant, in non-hospitalized immunocompromised_x000D_ outpatients with mild-to-moderate COVID-19
- Number of participants enrolled: 52
- Study enrolling from to
- Study includes follow-up for 3 months
Study Data
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Fragile population
- Hospital
- Emergency department
- SARS-CoV-2
- Acute COVID-19
- Pharmacological intervention
- Antivirals
- Monoclonal antibodies
- Nirmatrelvir/Ritonavir
- Remdesivir
- Sotrovimab
External Links
Other information
Funders/Sponsors:
- NextGenerationeU-MUR PNRR extended Partnership initiative on emerging infectious Diseases
The information was provided with the aid of the study investigators
If you would like to contact the Principal Investigator of the study please email: ccb@ateneo.univr.it
The data is updated up to